Company Overview and News

 
BioTime's (BTX) CEO Adi Mohanty on Q1 2018 Results - Earnings Call Transcript

2018-05-12 seekingalpha
Good day, ladies and gentlemen, and welcome to the BioTime's First Quarter Results Conference Call. As a reminder, this conference call is being recorded.

1
BTX / BioTime, Inc. BIOTIME, INC. 8-K (Current Report)

2018-05-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

 
BioTime (BTX): Moving Average Crossover Alert

2018-04-10 zacks
BioTime, Inc. (BTX - Free Report) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for BTX broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.

5
BioTime, Inc.: An Undervalued Regenerative Medicine Company

2018-04-09 seekingalpha
If approved, it would be the first therapy for dry AMD, which could be a $22 billion market in the United States.

 
BTX / BioTime, Inc. null

2018-03-29 sec.gov

 
BTX / BioTime, Inc. null

2018-03-29 sec.gov

 
BRIEF-BioTime Announces Cash Sale Of Ascendance Biotechnology

2018-03-27 reuters
* BIOTIME INC - AGEX RECEIVED APPROXIMATELY $3.2 MILLION UPON CLOSE OF ACQUISITION FOR ITS INTEREST IN ASCENDANCE

 
BTX / BioTime, Inc. null

2018-03-19 sec.gov

1
BioTime's (BTX) CEO Adi Mohantyon Q4 2017 Results - Earnings Call Transcript

2018-03-16 seekingalpha
Welcome to the BioTime’s Fourth Quarter and Full Year 2017 Results Conference Call. As a reminder, this conference call is being recorded.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 09066L105